Amgen Inc. (NASDAQ:AMGN) Shares Sold by Greenfield Savings Bank

Greenfield Savings Bank lowered its stake in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 5.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,672 shares of the medical research company’s stock after selling 204 shares during the quarter. Greenfield Savings Bank’s holdings in Amgen were worth $815,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Tanglewood Legacy Advisors LLC acquired a new position in Amgen in the 4th quarter worth approximately $26,000. Ruedi Wealth Management Inc. acquired a new position in Amgen in the 4th quarter worth approximately $27,000. Strategic Investment Solutions Inc. IL acquired a new position in Amgen in the 1st quarter worth approximately $28,000. GW&K Investment Management LLC increased its holdings in Amgen by 200.0% in the 4th quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock worth $32,000 after buying an additional 80 shares during the period. Finally, AXS Investments LLC acquired a new position in Amgen in the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 74.44% of the company’s stock.

Amgen Trading Up 2.0 %

Shares of NASDAQ:AMGN opened at $262.30 on Friday. Amgen Inc. has a 1 year low of $211.71 and a 1 year high of $296.67. The firm has a market capitalization of $140.30 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 3.23 and a beta of 0.61. The company has a debt-to-equity ratio of 8.76, a current ratio of 2.77 and a quick ratio of 2.48. The business’s 50 day moving average price is $246.49 and its 200-day moving average price is $237.31.

Amgen (NASDAQ:AMGNGet Free Report) last announced its earnings results on Thursday, August 3rd. The medical research company reported $5.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.44 by $0.56. Amgen had a net margin of 30.02% and a return on equity of 196.60%. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $6.66 billion. During the same quarter in the previous year, the company posted $4.65 EPS. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. On average, equities research analysts forecast that Amgen Inc. will post 18.35 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Friday, August 18th were given a dividend of $2.13 per share. The ex-dividend date was Thursday, August 17th. This represents a $8.52 annualized dividend and a dividend yield of 3.25%. Amgen’s payout ratio is 57.45%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on AMGN shares. HSBC started coverage on shares of Amgen in a report on Wednesday, September 6th. They issued a “buy” rating and a $320.00 price target on the stock. Oppenheimer restated an “outperform” rating and issued a $280.00 price objective on shares of Amgen in a research report on Tuesday, July 25th. Credit Suisse Group lowered their price objective on Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Mizuho upped their price objective on Amgen from $214.00 to $223.00 and gave the stock a “neutral” rating in a research report on Monday, August 14th. Finally, Barclays lowered their price objective on Amgen from $225.00 to $210.00 in a research report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $264.19.

Get Our Latest Research Report on AMGN

Insider Activity

In related news, EVP Murdo Gordon sold 9,558 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $262.43, for a total value of $2,508,305.94. Following the sale, the executive vice president now directly owns 44,308 shares in the company, valued at approximately $11,627,748.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.46% of the company’s stock.

Amgen Company Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Stories

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.